Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07664397 · ClinicalTrials.gov registry record · Phase 1
Imaging Study of [89Zr]DFO-YS5 for Cancer Detection
A Phase 1 study, sponsored by Robert Flavell, MD, PhD.
- Not yet
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT07664397 is a Phase 1 study that has not yet begun recruiting, run by Robert Flavell, MD, PhD. The registered enrollment target is 40 participants.
The verdict
NCT07664397, a Phase 1 study, has not yet begun recruiting, sponsored by Robert Flavell, MD, PhD.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
This is a single-center, pilot, PET-imaging study of the novel radiotracer 89Zirconium-89 DFO conjugated to the YS5 monoclonal antibody (\[89Zr\]DFO-YS5) in participants with nerve sheath tumor, bladder cancer, or advanced solid tumor neoplasms.
Interventions
- DRUG [89Zr]DFO-YS5
- PROCEDURE Positron Emission Tomography (PET)-Magnetic resonance imaging (MRI)
- PROCEDURE Positron Emission Tomography (PET)-Computerized tomography (CT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2026-08-01 |
| Est. Completion | 2029-09-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07664397
The ClinicalTrials.gov registry entry for NCT07664397 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Robert Flavell, MD, PhD, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which [89Zr]DFO-YS5 is the first listed.
NCT07664397 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07664397 about?
NCT07664397 is a clinical study titled "Imaging Study of [89Zr]DFO-YS5 for Cancer Detection". This is a single-center, pilot, PET-imaging study of the novel radiotracer 89Zirconium-89 DFO conjugated to the YS5 monoclonal antibody (\[89Zr\]DFO-YS5) in participants with nerve sheath tumor, bladder cancer, or advanced solid tumor neoplasms.
What is the current status of trial NCT07664397?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2026-08-01. Estimated completion is 2029-09-30.
What interventions are being tested in trial NCT07664397?
The interventions under investigation include: [89Zr]DFO-YS5 (DRUG), Positron Emission Tomography (PET)-Magnetic resonance imaging (MRI) (PROCEDURE), Positron Emission Tomography (PET)-Computerized tomography (CT) (PROCEDURE).
Who is sponsoring clinical trial NCT07664397?
This trial is sponsored by Robert Flavell, MD, PhD, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.